<DOC>
	<DOCNO>NCT02026219</DOCNO>
	<brief_summary>Ticagrelor non-thienophyridine , direct P2Y12 blocker potent clopidogrel associate less interindividual variability . In PLATO trial , find superior clopidogrel respect cardiovascular outcome total mortality without increase risk bleeding . More potent reversible receptor binding possible explanation superior outcome . Beside potent effect inhibition antiplatelet function , ticagrelor previously demonstrate increase adenosine level inhibit adenosine re-uptake tissue level induce adenosine triphosphate ( ATP ) release human red cell , stimulate vasodilation red blood cell .</brief_summary>
	<brief_title>Comparison Clopidogrel Ticagrelor Microvascular Dysfunction ST-Segment Elevation Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Males Females age 18 75 year STEMI patient treat percutaneous coronary intervention Able provide inform consent History stroke transient ischemic attack Platelet count &lt; 100 000/Î¼L Known Bleeding Diathesis Hematocrit &lt; 30 % &gt; 52 % Severe Liver Dysfunction Renal Insufficiency ( Creatinine Clearance &lt; 30ml/min ) Pregnant females Cardiogenic shock symptomatic hypotension sit SBP &lt; 95 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>